Clinical application of whole-genome sequencing of solid tumors for precision oncology

참고문헌 (66)

1. Malone, E. R., "Molecular profiling for precision cancer therapies", Genome Med, 12, pp.8~ (2020)
2. Bailey, M. H., "Comprehensive characterization of cancer driver genes and mutations", Cell, 173, pp.371~385 (2018)
3. ICGC, "TCGA Pan-Cancer Analysis of Whole Genomes Consortium", Pan-cancer analysis of whole genomes, 2020, pp.578, 82~93
4. Garraway, L. A., "Lessons from the cancer genome", Cell, 153, pp.17~37 (2013)
5. Slamon, D. J., "Human breast cancer : correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
6. Swain, S. M., "Targeting HER2-positive breast cancer : advances and future directions", Nat. Rev. Drug Discov, 22, pp.101~126 (2023)
7. Wolff, A. C., "Human epidermal growth factor receptor 2 testing in breast cancer", Arch. Pathol. Lab. Med, 147, pp.993~1000 (2023)
8. Frampton, G. M., "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing", Nat. Biotechnol, 31, pp.1023~1031 (2013)
9. Mosele, F., "Recommendations for the use of next-generation sequencing(NGS)for patients with metastatic cancers : a report from the ESMO Precision Medicine Working Group", Ann. Oncol, 31, pp.1491~1505 (2020)
10. Yates, L. R., "Translational genomics: practical applications of the genomic revolution in breast cancer", Clin. Cancer Res, 23, pp.2630~2639 (2017)
11. Abbasi, A., "Significance and limitations of the use of next generation sequencing technologies for detecting mutational signatures", DNA Repair, 107, pp.103200~ (2021)
12. "Target-enhanced whole-genome sequencing (TE-WGS) shows clinical validity equivalent to commercially available targeted oncology panel" (2023)[URL]
13. Nakagawa, H., "Whole genome sequencing analysis for cancer geno mics and precision medicine", Cancer Sci, 109, pp.513~522 (2018)
14. Jung, Y., "BWA-MEME : BWA-MEM emulated with a machine learning approach", Bioinformatics, 38, pp.2404~2413 (2022)
15. Cibulskis, K., "Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples", Nat. Biotechnol, 31, pp.213~219 (2013)
16. Kim, S., "Strelka2 : fast and accurate calling of germline and somatic variants", Nat. Methods, 15, pp.591~594 (2018)
17. Tate, J. G., "COSMIC : the catalogue of somatic mutations in cancer", Nucleic Acids Res, 47, pp.D941~D947 (2019)
18. Landrum, M. J., "ClinVar : public archive of relationships among sequence variation and human phenotype", Nucleic Acids Res, 42, pp.D980~D985 (2014)
19. Favero, F., "Sequenza : allele-specific copy number and mutation profiles from tumor sequencing data", Ann. Oncol, 26, pp.64~70 (2015)
20. Rausch, T., "DELLY : structural variant discovery by integrated paired-end and split-read analysis", Bioinformatics, 28, pp.i333~i339 (2012)
21. McLaren, W., "The ensembl variant effect predictor", Genome Biol, 17, pp.122~ (2016)
22. Chakravarty, D., "OncoKB : a precision oncology knowledge base", JCO Precis. Oncol, 1, pp.1~16 (2017)
23. Guo, Q., "The mutational signatures of formalin fixation on the human genome", Nat. Commun, 13, pp.4487~ (2022)
24. Alexandrov, L. B., "Deciphering signatures of mutational processes operative in human cancer", Cell Rep, 3, pp.246~259 (2013)
25. Alexandrov, L. B., "The repertoire of mutational signatures in human cancer", Nature, 578, pp.94~101 (2020)
26. Davies, H., "HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures", Nat. Med, 23, pp.517~525 (2017)
27. Niu, B., "MSIsensor : microsatellite instability detection using paired tumor normal sequence data", Bioinformatics, 30, pp.1015~1016 (2014)
28. Takahashi, T., "Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan", Cancer Sci, 114, pp.2524~2533 (2023)
29. Robert, N. J., "Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network", Lung Cancer, 166, pp.197~204 (2022)
30. Davoli, T., "Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy", Science, 355, pp.eaaf8399~ (2017)
31. Cortés-Ciriano, I., "Comprehensive analysis of chromothripsis in 2, 658 human cancers using whole-genome sequencing", Nat. Genet, 52, pp.331~341 (2020)
32. "ACMG SF Genes"[URL]
33. Ettinger, D. S., "Non-small cell lung cancer, Version 3.2022, NCCN clinical practice guidelines in oncology", J. Natl. Compr. Canc Netw, 20, pp.497~530 (2022)
34. Kopetz, S., "Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer", N. Engl. J. Med, 381, pp.1632~1643 (2019)
35. André, F., "Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer", N. Engl. J. Med, 380, pp.1929~1940 (2019)
36. Loriot, Y., "Erdafitinib in locally advanced or metastatic urothelial carcinoma", N. Engl. J. Med, 381, pp.338~348 (2019)
37. Shaw, A. T., "First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer", N. Engl. J. Med, 383, pp.2018~2029 (2020)
38. Camidge, D. R., "Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer", N. Engl. J. Med, 379, pp.2027~2039 (2018)
39. Peters, S., "Alectinib versus Crizotinib in Untreated ALK-Positive non-small-cell lung cancer", N. Engl. J. Med, 377, pp.829~838 (2017)
40. Lee, J. J.-K., "Tracing oncogene rearrangements in the mutational history of lung adenocarcinoma", Cell, 177, pp.1842~1857 (2019)
41. Xiang, Y., "Therapeutic advances of rare ALK fusions in non-small cell lung cancer", Curr. Oncol, 29, pp.7816~7831 (2022)
42. Maio, M., "Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers : updated analysis from the phase II KEYNOTE-158 study", Ann. Oncol, 33, pp.929~938 (2022)
43. Fizazi, K., "First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer : the phase 3 TALAPRO-2 trial", Nat. Med, 30, pp.257~264 (2024)
44. Chi, K. N., "Niraparib and Abiraterone acetate for metastatic castration resistant prostate cancer", J. Clin. Oncol, 41, pp.3339~3351 (2023)
45. Clarke, N. W., "Abiraterone and Olaparib for metastatic castration-resistant prostate cancer", NEJM evid, 1, pp.EVIDoa2200043~ (2022)
46. Kim, H., "Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers", Nat. Genet, 52, pp.891~897 (2020)
47. Subbiah, V., "FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF", FGFR alterations and advanced malignancies, 2022, pp.33, 522~533
48. Nakamura, K., "Olaparib monotherapy for BRIP1-mutated high-grade serous endometrial cancer", JCO Precis. Oncol, 4, pp.283~290 (2020)
49. Galland, L., "Efficacy ofplatinum-based chemotherapyin metastatic breastcancer and HRD biomarkers : utility of exome sequencing", NPJ Breast Cancer, 8, pp.28~ (2022)
50. Huang, L., "KRAS mutation : from undruggable to druggable in cancer", Signal Transduct. Target. Ther, 6, pp.386~ (2021)
51. Hong, D. S., "KRASG12C inhibition with sotorasib in advanced solid tumors", N. Engl. J. Med, 383, pp.1207~1217 (2020)
52. Bekaii-Saab, T. S., "Adagrasib in advanced solid tumors harboring a KRASG12C mutation", J. Clin. Oncol, 41, pp.4097~4106 (2023)
53. Lièvre, A., "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer", Cancer Res, 66, pp.3992~3995 (2006)
54. Murray, S., "Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer : an analytical database", J. Thorac. Oncol, 3, pp.832~839 (2008)
55. Alexandrov, L. B., "Mutational signatures associated with tobacco smoking in human cancer", Science, 354, pp.618~622 (2016)
56. Paz-Ares, L., "First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer(CheckMate 9LA) : an international, randomised, open-label, phase 3 trial", Lancet Oncol, 22, pp.198~211 (2021)
57. Aoki, K., "Adenomatous polyposis coli(APC) : a multi-functional tumor suppressor gene", J. Cell Sci, 120, pp.3327~3335 (2007)
58. Akhoundova, D., "The grand challenge of moving cancer whole genome sequencing into the clinic", Nat. Med, 30, pp.39~40 (2024)
59. Druliner, B. R., "Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methy lome alterations", Sci. Rep, 8, pp.3161~ (2018)
60. "Whole genome mutational analysis for tumor-informed ctDNA based MRD surveillance, treatment monitoring and biological characterization of urothelial carcinoma" (2023)[URL]
61. Leroy, K., "Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples(REALM study)", PLoS ONE, 18, pp.e0291495~ (2023)
62. Vogelstein, B., "Cancer genome landscapes", Science, 339, pp.1546~1558 (2013)
63. Steuten, L., "Cost effec tiveness of multigene panel sequencing for patients with advanced non-small cell lung cancer", JCO Clin. Cancer Inf, 3, pp.1~10 (2019)
64. Pennell, N. A., "Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model", JCO Precis. Oncol, 3, pp.1~9 (2019)
65. Vanderpoel, J., "Total cost of testing for genomic alterations associated with next generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer", J. Med. Econ, 25, pp.457~468 (2022)
66. Pennisi, E., "Upstart DNA sequencers could be a"game changer"", Science, 376, pp.1257~1258 (2022)

관련 논문AI추천